Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169910443> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2169910443 endingPage "D23" @default.
- W2169910443 startingPage "D14" @default.
- W2169910443 abstract "Significant developments have taken place over the past 15 years with respect to greater understanding of ischaemic risk in non-ST-segment elevation (NSTE) acute coronary syndrome (ACS) and respective management strategies. This includes recognition of the clinical benefit of an early invasive strategy and of the value of addressing various antiplatelet targets in the approach to pharmacotherapy. The guidelines focused on management of NSTE-ACS advocate the role of dual antiplatelet therapy with a recommendation for triple antiplatelet therapy, including a glycoprotein (GP) IIb/IIIa inhibitor (GPI), in patients who are determined to be at an elevated risk for ischaemic events. This may include those who are elderly, have a history of diabetes and/or renal impairment, and have elevated cardiac biomarkers (e.g. troponin) or ST-segment deviation at diagnosis. While triple antiplatelet therapy has demonstrated significant improvement in clinical outcomes in patients with NSTE-ACS, there is concern over the potential for an increase in haemorrhagic complications. Newer pharmacotherapies such as prasugrel and ticagrelor have demonstrated significantly greater efficacy as compared with clopidogrel in patients with NSTE-ACS deemed as high risk, although the incidence of certain bleeding complications was significantly increased with both of these agents. Additionally, efficacy has not yet been proved when compared with higher doses of clopidogrel, which has been shown to offer significant clinical benefits in patients who underwent percutaneous coronary intervention. Thus, a regimen of triple antiplatelet therapy including a GPI should remain a strong consideration for standard therapy in patients at high risk for ischaemic events, even in the prasugrel and ticagrelor era." @default.
- W2169910443 created "2016-06-24" @default.
- W2169910443 creator A5076782898 @default.
- W2169910443 date "2010-09-01" @default.
- W2169910443 modified "2023-09-23" @default.
- W2169910443 title "Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome" @default.
- W2169910443 cites W108314047 @default.
- W2169910443 cites W117662345 @default.
- W2169910443 cites W1573872903 @default.
- W2169910443 cites W1979083612 @default.
- W2169910443 cites W1990864736 @default.
- W2169910443 cites W1994506260 @default.
- W2169910443 cites W2021598528 @default.
- W2169910443 cites W2033376206 @default.
- W2169910443 cites W2034051654 @default.
- W2169910443 cites W2041936661 @default.
- W2169910443 cites W2042318890 @default.
- W2169910443 cites W2045713748 @default.
- W2169910443 cites W2045826820 @default.
- W2169910443 cites W2059136191 @default.
- W2169910443 cites W2060258953 @default.
- W2169910443 cites W2083344252 @default.
- W2169910443 cites W2095901832 @default.
- W2169910443 cites W2109390167 @default.
- W2169910443 cites W2131370832 @default.
- W2169910443 cites W2138696762 @default.
- W2169910443 cites W2140501627 @default.
- W2169910443 cites W2143147344 @default.
- W2169910443 cites W2147270034 @default.
- W2169910443 cites W2152823642 @default.
- W2169910443 cites W2157123954 @default.
- W2169910443 cites W2166905943 @default.
- W2169910443 cites W2169387542 @default.
- W2169910443 cites W2395313915 @default.
- W2169910443 cites W3022148767 @default.
- W2169910443 cites W4237892021 @default.
- W2169910443 cites W4254719698 @default.
- W2169910443 cites W43843458 @default.
- W2169910443 cites W58419149 @default.
- W2169910443 cites W979638655 @default.
- W2169910443 doi "https://doi.org/10.1093/eurheartj/suq021" @default.
- W2169910443 hasPublicationYear "2010" @default.
- W2169910443 type Work @default.
- W2169910443 sameAs 2169910443 @default.
- W2169910443 citedByCount "1" @default.
- W2169910443 countsByYear W21699104432014 @default.
- W2169910443 crossrefType "journal-article" @default.
- W2169910443 hasAuthorship W2169910443A5076782898 @default.
- W2169910443 hasBestOaLocation W21699104431 @default.
- W2169910443 hasConcept C126322002 @default.
- W2169910443 hasConcept C164705383 @default.
- W2169910443 hasConcept C177713679 @default.
- W2169910443 hasConcept C2777698277 @default.
- W2169910443 hasConcept C500558357 @default.
- W2169910443 hasConcept C71924100 @default.
- W2169910443 hasConceptScore W2169910443C126322002 @default.
- W2169910443 hasConceptScore W2169910443C164705383 @default.
- W2169910443 hasConceptScore W2169910443C177713679 @default.
- W2169910443 hasConceptScore W2169910443C2777698277 @default.
- W2169910443 hasConceptScore W2169910443C500558357 @default.
- W2169910443 hasConceptScore W2169910443C71924100 @default.
- W2169910443 hasIssue "Suppl D" @default.
- W2169910443 hasLocation W21699104431 @default.
- W2169910443 hasOpenAccess W2169910443 @default.
- W2169910443 hasPrimaryLocation W21699104431 @default.
- W2169910443 hasRelatedWork W2187342990 @default.
- W2169910443 hasRelatedWork W2231277951 @default.
- W2169910443 hasRelatedWork W2369582584 @default.
- W2169910443 hasRelatedWork W2596660188 @default.
- W2169910443 hasRelatedWork W2737074397 @default.
- W2169910443 hasRelatedWork W2760815731 @default.
- W2169910443 hasRelatedWork W2761476198 @default.
- W2169910443 hasRelatedWork W2771673812 @default.
- W2169910443 hasRelatedWork W3013716928 @default.
- W2169910443 hasRelatedWork W3141700921 @default.
- W2169910443 hasVolume "12" @default.
- W2169910443 isParatext "false" @default.
- W2169910443 isRetracted "false" @default.
- W2169910443 magId "2169910443" @default.
- W2169910443 workType "article" @default.